At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 87 enrolled
Drug / intervention
Sargramostim +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.
In Brief
A Phase 4 clinical trial evaluating Sargramostim and Control for COVID-19. Completed, enrolled 87 participants across 4 sites.
Detailed Summary
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesBelgium
CollaboratorsFlemish institute of biotechnology (VIB)
Timeline
Phase 4CompletedFinished
202120222023202420252026
Enrollment StartMar 2020
First PostedMar 2020
Primary CompletionSep 2020
Study CompletionFeb 2021
TodayJul 2026
First PostedMar 30, 2020
Enrollment StartMar 24, 2020
Primary CompletionSep 28, 2020
Study CompletionFeb 26, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.3 years ago
Interventions
Sargramostimdrug
Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration
Controlother
Standard of care